Company

Board of Directors

Sol J. Barer, Ph.D.
Chairman of the Board of Directors

Dr. Barer spent most of his professional career with the Celgene Corporation. He was Chairman from January 2011 until June 2011, Executive Chairman from June 2010 until Jan 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer was the founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene.

Dr. Barer serves as Chairman of the Board of the public companies Edge Therapeutics (neuro-critical care therapeutics), InspireMD (stents) and Medgenics (precision medicine) and private company Centrexion (pain therapeutics), is Lead Director of ContraFect (anti-infectives), and is on the Board of Directors of the public companies Amicus Therapeutics (rare diseases) and Teva Pharmaceutical Industries. He is an advisor to biopharma companies.

In 2011 Dr. Barer was Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee which resulted in sweeping changes in the structure of New Jersey’s medical schools and public research universities. He previously served as a Commissioner of the NJ Commission on Science and Technology. He was a member of the Board of Trustees of Rutgers University (until 2013). He also served two terms as Chair of the Board of Trustees of BioNJ (2010-2012) the New Jersey biotechnology organization.

Dr. Barer was named to the “Worldview 100” (Scientific American’s 100 most influential figures in today’s world of biotechnology) in 2015, named one of “25 Leadership Legends of NJ” (NJBiz) in 2012, “The 50 Most Powerful People in N.J. Health Care,” in 2012, inducted into the NJBiz Hall of Fame in 2011 and was named as one of NJ’s top 10 scientists by New Jersey Business in 2008.

Eugene A. Bauer, M.D.
Director

Dr. Eugene Bauer has been a member of Medgenics Board since March 2001. He is the Lucy Becker Professor (Emeritus) in the School of Medicine at Stanford University, having served as Vice President for Medical Affairs (1997-2001) and Dean of the School of Medicine (1995-2001) at Stanford University and as Chair of the Department of Dermatology at the Stanford University School of Medicine from 1988-1995.

Currently, Dr. Bauer is Founder, Chief Medical Officer and a member of the Board of Directors of Dermira, Inc. (Nasdaq: DERM). Dr. Bauer is also immediate-past President & Chief Medical Officer of Peplin, Inc., a position he held from 2008 to December 2009, when Peplin was acquired by LEO Pharma. Prior to Peplin, he was founding Chief Executive Officer of Neosil, Inc., also a development stage pharmaceutical company that was acquired by Peplin, Inc., in 2008. He was a co-founder and emeritus member of the board of directors of Connetics Corporation (Nasdaq: CNCT), a publicly traded, dermatology-focused therapeutics company which was acquired by Steifel Laboratories and later sold to GlaxoSmithKline, Inc.

For 25 years Dr. Bauer was an NIH-funded investigator and served on review groups at the National Institutes of Health, including as a member of the Advisory Council for the National Institute of Arthritis and Musculoskeletal and Skin Disease. He also served as a member of the Board of Scientific Counselors of the Division of Cancer Biology, Diagnosis and Centers of the National Cancer Institute.

Dr. Bauer received an M.D. from Northwestern University. He has been elected to several honorific societies, including the National Academy of Medicine. He has published more than 200 scientific articles and book chapters and has been honored by the Society for Investigative Dermatology (the Montagna Award and the Stephen Rothman Award), by the American Academy of Dermatology (the Sulzberger Award), and by Northwestern University (Alumni Merit Award and FSM Distinguished Alumnus Award).

Isaac Blech
Director

Mr. Blech is a renowned biotechnology entrepreneur, who, over the past 35 years, has founded some of the leading companies in biotechnology. These companies have produced major advances in a broad array of diseases, including the diagnosis of Chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and a wide variety of cancers and hematological diseases. The companies he established include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation and Genetics Systems Corporation. Mr. Blech is currently a Director and Vice Chairman and/or major investor in some of the most innovative health care companies today.

Alastair Clemow, Ph.D.
Director

Dr. Clemow was appointed to the Medgenics' Board in August 2010. He serves as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair. Previously, he held positions of president and chief executive officer in a number of companies that he helped found, including Nexgen Spine, Inc., which developed an artificial spinal disc; Gelifex, Inc., which developed an innovative spinal nucleus replacement implant and which was acquired in 2004 by Synthes Spine, Inc.; and Minimally Invasive Surgical Technologies, Inc., which developed a novel series of implants for minimally invasive total knee replacement and which was acquired in 2005 by MAKO Surgical Corp.

From 2000 to 2004, Dr. Clemow served as Principal of Tanton Technologies, Inc., an organization that provided strategic and technical assessment of new medical device opportunities for large, mid-cap and early stage development companies. From 1981 to 2000, Dr. Clemow held numerous positions with Johnson & Johnson, including Vice President of Worldwide Business Development for Ethicon Endo-Surgery, Inc.; Vice President of New Business Development for Johnson & Johnson Professional, Inc.; and Director of Research and Development of Johnson & Johnson Orthopedics. In those capacities, Dr. Clemow was responsible for acquiring or developing what today represents billions of dollars of Johnson & Johnson revenue.

Dr. Clemow serves or has served on the boards of numerous private and public companies including Encore Medical; Echo Healthcare Acquisition Corp.; BioMedical Enterprises, Inc.; and Kinetic Muscles, Inc.

Dr. Clemow holds an M.B.A. in Finance from Columbia University and a Ph.D. in Metallurgy from University of Surrey, Guildford, U.K.

Michael F. Cola
President, Chief Executive Officer, and Director

Mr. Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company.

Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, and currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia. Mr. Cola also served on the Life Sciences Pennsylvania Board (formerly named Pennsylvania Bio) from 2009-2015.

Barbara Duncan
Director

Ms. Duncan served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. from May 2009 through June 2016. She previously served in a series of positions with increasing responsibilities at DOV Pharmaceuticals, Inc. including as Chief Executive Officer, Chief Financial Officer and Treasurer. Before that, she served as Vice President of Corporate Finance – Global Healthcare at Lehman Brothers Inc. and Director of Corporate Finance at SBC Warburg Dillon Read Inc. Ms. Duncan holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University. Ms Duncan currently serves as director of Adaptimmune Therapeutics plc, a NASDAQ listed biopharmaceutical company.

Wilbur H. (Bill) Gantz
Director

Mr. Gantz is President of PathoCapital, an investor in healthcare companies. He previously was Executive Chairman of Naurex Inc., which was sold to Allergan in 2015. He also served as Executive Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., which was sold to Lundbeck, AG in 2009, and, as Chairman, Chief Executive Officer and President of PathoGenesis Corporation, a biopharmaceutical company that was sold to Chiron, Inc. in 2000. Prior to founding PathoGenesis, from 1987 to 1992 he served as President of Baxter International, Inc., a manufacturer and marketer of healthcare products. He joined Baxter in 1966 and held various management positions, including Vice President, Europe and President, International Division, prior to being named Executive Vice President and Chief Operating Officer in 1980.

Mr. Gantz holds a BA degree from Princeton University, where he graduated cum laude, and an M.B.A. from Harvard Business School.

Joseph J. Grano, Jr.
Director

Mr. Grano is Chairman and CEO of Centurion Holdings LLC, a provider of advisory services to public and private clients on all facets of business strategy and capital markets access. Previously he was Chairman and CEO of UBS Financial Services Inc. UBS/PaineWebber, subsequent to the merger between UBS and PaineWebber in 2000. Prior to joining PaineWebber he held various senior management positions at Merrill Lynch including Director of National Sales.

Mr. Grano is the former Chairman of the Board of Governors of NASD and was a member of the NASD’s Executive Committee. He was appointed by President George W. Bush in 2002 to serve as the Chairman of the Homeland Security Advisory Council, a position he held until August 2005.

Mr. Grano was a captain in the U.S. Special Forces (Green Berets), and is a member of the City University of New York's Business Leadership Council and a former member of the National Board of D.A.R.E. He holds honorary Doctor of Law degrees from Pepperdine University and Babson College, as well as an honorary Doctor of Human Letters degree from Queens College. He serves on the Board of Directors of the YMCA of Greater New York and of Lenox Hill Hospital in New York City.